Joana Kokalari
I find true meaning in helping teams work better together, knowing that in healthcare, every improvement can ultimately make a […]
Lena Kapteina
I am passionate about bridging cutting-edge science and patient access, because the gap between the two is where I can
Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
Author: Ben Barron-Millar, Senior Consultant, Value Communication The National Institute for Health and Care Excellence (NICE) has published its Annual
Christian Schröer
I am passionate about translating scientific evidence into meaningful insights that connect healthcare decision-making with the needs of patients. I
Ansgar Oberheide
What motivates me most is bridging cutting-edge science and real-world application to improve patients’ lives, while recognising that enabling market access in
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
Author: Ben Barron-Millar, Senior Consultant, Value Communication A summary of NICE’s disease-specific reference case extension for managing overweight and obesity
The German AMNOG Reset. Decoded. What the BStabG (GKV-Spargesetz) Changes – A Strategic Reading for Market Access Leaders
Date: 16 July 2026 Time: 13:30 – 14:00 CET Location: Online The BStabG (GKV-Spargesetz) is not another incremental amendment –
Winning in a Changing HTA Landscape: What HTAi 2026 Means for Strategy, Evidence, and Access
At HTAi 2026 in Istanbul, one message came through clearly: delivering high-quality health technology assessment (HTA) is no longer the
Two EU JCAs Discontinued This Week! What Happened & Why It Matters
The EU HTA Regulation (EU) 2021/2282 was designed to transform clinical assessment in Europe through Joint Clinical Assessments (JCAs). But
Whitepaper: Why Oncology Strategy Must Now Start Earlier, Think Wider, and Integrate Market Access from the Beginning
Strategic Implications for Pharma & Biotech from ASCO 2026 Author: Univ.-Prof. Dr. Matthias P. Schönermark, Chief Strategy Officer Every
